• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Sucampo Pharmaceuticals, Inc. (SCMP)

    -NasdaqGM
    14.50 Up 0.50(3.57%) Mar 27, 4:00PM EDT
    |After Hours : 14.50 0.00 (0.00%) Mar 27, 4:33PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Sucampo Pharmaceuticals, Inc.
    4520 East West Highway
    3rd Floor
    Bethesda, MD 20814
    United States - Map
    Phone: 301-961-3400
    Fax: 301-961-3440
    Website: http://www.sucampo.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:80

    Business Summary 

    Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, as well as other therapeutic applications of drug technologies. The company’s product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sucampo Pharmaceuticals, Inc.

    Corporate Governance 
    Sucampo Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 4. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 7; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Ryuji Ueno M.D., Ph.D., Ph.D., 61
    Co-Founder, Chairman Emeritus and Scientific Advisor
    865.00K0.00
    Mr. Andrew P. Smith FCMA, CGMA, 52
    Chief Financial Officer
    405.00K192.00K
    Mr. Thomas J. Knapp J.D., 62
    Chief Legal Officer, Exec. VP and Corp. Sec.
    467.00K0.00
    Mr. Stanley G. Miele , 51
    Sr. VP of Sales & Marketing and Pres of Sucampo Pharma Americas LLC
    350.00K477.00K
    Mr. Peter S. Greenleaf , 45
    Chief Exec. Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders